Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0948265 (
metabolic syndrome
)
24,271
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Our previous study had suggested
Tribbles homolog 3
(
TRB3
) might be involved in
metabolic syndrome
via adipose tissue. Given prior studies, we sought to determine whether
TRB3
plays a major role in adipocytes and adipose tissue with beneficial metabolic effects in obese and diabetic rats. Fully differentiated 3T3-L1 adipocytes were incubated to induce insulin resistant adipocytes. Forty male Sprague-Dawley rats were all fed high-fat (HF) diet. Type 2 diabetic rat model was induced by high-fat diet and low-dose streptozotocin (STZ). Compared with control group, in insulin resistant adipocytes, protein levels of insulin receptor substrate-1(IRS-1), glucose transporter 4(GLUT4) and phosphorylated-AMP-activated protein kinase (p-AMPK)were reduced,
TRB3 protein
level and triglyceride level were significantly increased, glucose uptake was markedly decreased.
TRB3
silencing alleviated adipocytes insulin resistance. With
TRB3
gene silencing, protein levels of IRS-1, GLUT4 and p-AMPK were significantly increased in adipocytes.
TRB3
gene silencing decreased blood glucose, ameliorated insulin sensitivity and adipose tissue remodeling in diabetic rats.
TRB3
silencing decreased triglyceride, increased glycogen simultaneously in diabetic epididymal and brown adipose tissues (BAT). Consistently, p-AMPK levels were increased in diabetic epididymal adipose tissue, and BAT after
TRB3
-siRNA treatment. TRB3silencing increased phosphorylation of Akt in liver, and improved liver insulin resistance.
...
PMID:TRB3 gene silencing activates AMPK in adipose tissue with beneficial metabolic effects in obese and diabetic rats. 2847 19